SCHEMBL3377920

SCHEMBL3377920

CC(OC(=O)NC(C)(C)C)C1CC(Oc2ccc(CN3CCCC3)c(Cl)c2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.40
HRH1 P35367 3/20 0.38
CCR3 P51677 3/20 0.38
KCNH2 Q12809 2/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
EPHX2 P34913 2/20 0.36
GSK3B P49841 1/20 0.35
PLA2G1B P04054 1/20 0.35
POLB P06746 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
THRB P10828 1/20 0.35
ADRB2 P07550 1/20 0.35
S1PR1 P21453 1/20 0.34
PRKX P51817 1/20 0.34
ACVR1 Q04771 1/20 0.34
S1PR5 Q9H228 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377916 1.00 HRH3 (0.40) HRH3HRH1CCR3KCNH2MEN1
SCHEMBL3430593 0.86 HRH3 (0.41) HRH3HRH1CCR3KCNH2MEN1
SCHEMBL3430591 0.86 HRH3 (0.41) HRH3HRH1CCR3KCNH2MEN1
SCHEMBL3378818 0.80 HRH3 (0.53) HRH3HRH1CCR3KCNH2MEN1
SCHEMBL3430594 0.77 GSK3B (0.45) HRH3HRH1CCR3KCNH2EPHX2
SCHEMBL3377768 0.76 HRH3 (0.56) HRH3HRH1CCR3KCNH2MEN1
SCHEMBL3380239 0.75 HRH3 (0.54) HRH3HRH1CCR3KCNH2MEN1
SCHEMBL3375245 0.75 HRH3 (0.56) HRH3HRH1CCR3KCNH2EPHX2
SCHEMBL3378460 0.74 HRH3 (0.44) HRH3HRH1CCR3KCNH2EPHX2
SCHEMBL4649156 0.74 HRH3 (0.43) HRH3HRH1CCR3KCNH2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 EP disclosed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 US disclosed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS HRH3, HRH4, HRH2 HRH3 1/4885HRH1 4/4885CCR3 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.